Umuthi osetshenziselwa ukuphuza utshwala ungelapha umdlavuza ngokukhomba ama-macrophages
Iqembu locwaningo eliholwa ngu-Yuya Terashima wase-Tokyo University lithole ukuthi umuthi osetshenziselwa ukuphuza utshwala ungelapha umdlavuza ngokukhomba ama-macrophages.
Njengokwemininingwane ye-WHO kanye ne-International Agency for Research on Cancer (IARC), kube nezigameko ezintsha eziyizigidi eziyi-18.1 nokufa kwabantu abayizigidi eziyi-9.6 ngo-2018. Indoda eyodwa kwabayi-5 kanye noyedwa kwabasi-6 kwabesifazane emhlabeni jikelele baba nomdlavuza ngesikhathi sokuphila kwabo, kanti oyedwa kwabayi-8 owesifazane oyedwa kwabangu-11 ubulawa yilesi sifo. Emhlabeni jikelele, inani labantu abaphila phakathi neminyaka emi-5 yokuxilongwa komdlavuza, okubizwa ngokuthi ukusabalala kweminyaka emi-5, lilinganiselwa ezigidini ezingama-43.8.
Umdlavuza we-Lung wuhlobo lomdlavuza oluvame kakhulu emadodeni (14.5%) kanye nembangela yokufa ehamba phambili emadodeni (22%). Lokhu kulandelwa umdlavuza wendlala (13.5%) , umdlavuza colorectal (10.9%), & umdlavuza wesibindi (9.5%). Kwabesifazane, umdlavuza webele cishe u-25%, ulandelwa umdlavuza wamaphaphu (13.8%), umdlavuza we-colorectal (9.5%), nomdlavuza womlomo wesibeletho (6.6%).
Ukwakha a ukwelashwa ukulwa ne-malignant ukukhula kusengenye yezinkinga ezinzima kakhulu ocwaningweni lwezokwelapha. Ukukhula okulimazayo kukweleta ubuntu bakho obunedumela elibi ngenxa yendlela amangqamuzana esifo asebenzisa ngayo uhlaka lwalowo osokhaya ukuze athuthuke futhi asabalale, ekugcineni abe nobudlova. Amaseli angenakuthinteka njengama-macrophage, avame ukulwa ukuze aqinisekise amangqamuzana avamile, alawulwa amangqamuzana esifo esiyingozi, futhi agcwalise umhlaba azungeze izimila, aphenduke ama-macrophage ahlobene ne-tumor (TAMs).
Empeleni, kwatholakala ukuthi izicubu eziyingozi zeziguli immunotherapy awuzange uthele empeleni wawucebile kuma-macrophage, eqinisekisa ukuxhumana phakathi kwesifo nama-TAM. Yilawa ma-TAM akhiqiza amaprotheni ahlaba umkhosi njengama-chemokines futhi aqalise ukukhishwa kwe-inhibitory resistant checkpoint okwenza i-immunosuppressive. isisu isimo, esiqinisekisa ukukhula kwamaseli ayingozi futhi sivumele ukukhula kwawo okusheshayo. Njengoba ama-TAM ekhuthaza ukusabalala kwe-malignant amaseli okukhula, ukuwaphatha njengendlela yokwelapha yokulwa nesifo sekucatshangelwe kamuva nje.
Ithimba labacwaningi abavela e-Tokyo University of Science, ngaphansi kokuqondisa kuka-Yuya Terashima libone lokhu njengethuba lokubheka umkhakha wokwenza imithi emisha elwa nokuvuvukala. Umsebenzi wabo wasekuqaleni ku-Nature Immunology 2005 wembula ukudalulwa kwelinye iphrotheni eyinhloso ebizwa ngokuthi FROUNT, exhunywe kuzinkombandlela nokuthuthukiswa kwama-TAM. Ngale ndlela, i-FROUNT yayixhunyaniswe ngokuqondile nemithetho ye-TAM ngoba yandisa "ukusayinda kwe-chemokine," uhlobo lokuxhumana kwamaseli oludingekayo ekuqoqeni nasekunyakazeni kwe-TAM.
Ngaleso sikhathi, ukuze kwehliswe noma yiziphi izimpawu, iqembu liphinde lakha indlela yokuzimela yokukhawulela umthelela we-FROUNT ekuhambeni kwe-chemokine ngokucindezela ukuxhumana phakathi kwakho kokubili. Iqembu lihlole amamiksi angu-131,200 futhi lagxila ku-disulfiram, umuthi osetshenziselwa ukwelapha ukusetshenziswa kabi kotshwala, futhi okubhekiselwa kuwo ngamandla awo njengesitha se-tranquilizer yokukhula eyingozi. Lo muthi utholwe ubophela ngokusemthethweni kusayithi elingu-FROUNT, okwenza ukuthi i-FROUNT ingafinyeleleki ngokusebenzisana nezingxenye zokuhlaba umkhosi kwe-chemokine.
Ecabangela imiphumela, uTerashima uyacacisa, “Lapho izama amagundane, i-disulfiram yacindezela ukuthuthukiswa kwama-macrophages futhi yavimbela ukuthuthukiswa kwamangqamuzana okukhula ayingozi. Ngakho-ke, lokho esikutholile kuveza indlela entsha yokwelapha umdlavuza engamisa ukukhula kwamangqamuzana omdlavuza okunzima ukuthi amasosha omzimba awabone lapho esetshenziswa kanye ne-disulfiram.
Ngethemba, sizobona okusha zokwelapha ekwelapheni umdlavuza.
